NETB-EA
Candidate Overview
The Khader Lab in collaboration with BlueWillow Biologics Inc., have developed an intranasal booster sub-unit, mucosal vaccine comprising of Mtb immunodominant antigens Early secreted antigenic target 6 kDa andAntigen 85B together with nanoemulsion adjuvant NE01-NETB-EA.
Sponsor / Lead Developer: The University of Chicago, USA.
Development partner(s): BlueWillow Biologics Inc.
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection
Target Population(s): Adolescents and Adults
Target Route of Administration: Intranasal
Immune tissue localization: Lung
Immunological responses: B-cell/Antibody and T-cell
Preclinical Animal Models: Mouse and Nonhuman primate
Intended to elicit trained immunity: No
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell B-cell/Antibody |
|
| T-cell phenotype | CD4 | |
| T-cell functional profile | IFN-γ IL-17 |
|
| Characteristics of B-cell response | Subclass IgG2a in mice which is equal with IgG1 in human. | |
| Preferential immune tissue localization | Lung |
|
| Trained immunity | No | |